Characterization of QuantiFERON-TB-Plus Results in Patients with Tuberculosis Infection and Multiple Sclerosis

Background: Disease-modifying drugs (DMDs) for multiple sclerosis (MS) slightly increase the risk of tuberculosis (TB) disease. The QuantiFERON-TB-Plus (QFT-Plus) test is approved for TB infection (TBI) screening. Currently, there are no data available regarding the characterization of QFT-Plus resp...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Neurology international Ročník 17; číslo 8; s. 119
Hlavní autori: Petruccioli, Elisa, Prosperini, Luca, Ruggieri, Serena, Vanini, Valentina, Salmi, Andrea, Cuzzi, Gilda, Galgani, Simonetta, Haggiag, Shalom, Tortorella, Carla, Parisi, Gabriella, D’Agostino, Alfio, Gualano, Gina, Palmieri, Fabrizio, Gasperini, Claudio, Goletti, Delia
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland MDPI AG 02.08.2025
MDPI
Predmet:
Antigens
Autoimmune diseases
Drugs
HIV
Human immunodeficiency virus
IFN-γ
Immune response
Immune system
Infections
Infectious diseases
Inflammatory diseases
multiple sclerosis
Population
QFT-Plus
Software
Tuberculosis
IFN-γ
QFT-Plus
MS
multiple sclerosis
tuberculosis
ISSN:2035-8377, 2035-8385, 2035-8377
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background: Disease-modifying drugs (DMDs) for multiple sclerosis (MS) slightly increase the risk of tuberculosis (TB) disease. The QuantiFERON-TB-Plus (QFT-Plus) test is approved for TB infection (TBI) screening. Currently, there are no data available regarding the characterization of QFT-Plus response in patients with MS. Objectives: This study aimed to compare the magnitude of QFT-Plus responses between patients with MS and TBI (MS-TBI) and TBI subjects without MS (NON-MS-TBI). Additionally, discordant responses to TB1/TB2 stimulation were documented. Results were evaluated considering demographic and clinical data, particularly the impact of DMDs and the type of TB exposure. Methods: Patients with MS (N = 810) were screened for TBI (2018–2023). Thirty (3.7%) had an MS-TBI diagnosis, and 20 were recruited for the study. As a control group, we enrolled 106 NON-MS-TBI. Results: MS-TBI showed significantly lower IFN-γ production in response to TB1 (p = 0.01) and TB2 stimulation (p = 0.02) compared to NON-MS-TBI. The 30% of TB2 results of MS-TBI fell into the QFT-Plus grey zone (0.2–0.7 IU/mL). Only 7% of NON-MS-TBI showed this profile (p = 0.002). Conclusions: MS-TBI had a lower QFT-Plus response and more borderline results compared to NON-MS-TBI. Future studies should clarify the significance of the borderline results in this vulnerable population to improve QFT-Plus accuracy regarding sensitivity, specificity, and TB prediction.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2035-8377
2035-8385
2035-8377
DOI:10.3390/neurolint17080119